Wednesday, August 12, 2020 7:26:00 PM
Update On March 6, 2020 after the stock market closed Sorrento disclosed that the company had filed a legal action against Patrick Soon-Shiong in Los Angeles Superior Court, asserting claims for fraudulent inducement and common law fraud, arising out of Dr. Soon-Shiong’s purchase of the drug CynviloqTM from the Company in May 2015. The action alleges that, among other things, Dr. Soon-Shiong acquired the drug Cynviloq for the purpose of halting its progression to the market. In connection with filing this civil action in the Los Angeles Superior Court, where the Company will have the right to a jury trial against Dr. Soon-Shiong, the Company has dismissed Dr. Soon-Shiong from the related, ongoing arbitration against NantPharma, LLC.
I discussed this with my attorney friend he feels this is excellent news and good advice from Sorrento's legal team he suggested Dr Patrick Soon-Shiong could very well pay much much more possibly 5 times the original $1 billion arbitration suit, reason being is a jury could take severe action against Soon-Shiong for keeping a cancer drug off the market, also the legal action is directly against Soon-Shiong so he can't file bankruptcy given the fact he is worth $6 to $12 Billion. Sorrento's hired Hueston Hennigan LLP Harvard law school Steven Feldman who is recognized by multiple publications as one of the nation’s top litigators under 40, Steven Feldman uses his deep experience in the courtroom to help clients develop creative and aggressive case strategies with the goal of obtaining their desired result—whether it be a trial victory or achieving a favorable settlement. He is a trusted litigator for Fortune 500 companies, well-known venture-backed companies and individuals, such as Amgen and T-Mobile.
https://seekingalpha.com/instablog/51307855-tradeinvestments2019/5419913-full-story-why-sorrento-therapeutics-offers-tremendous-upside-cbs-news-t-v-special-report-on
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM
- Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patients with locally advanced/metastatic solid tumors at the A • GlobeNewswire Inc. • 06/05/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM